Hypogonadism with 47 XXY is a feature of
**Question:** Hypogonadism with 47 XXY is a feature of
A. Klinefelter syndrome
B. Turner syndrome
C. Congenital adrenal hyperplasia
D. Polycystic ovary syndrome (PCOS)
**Correct Answer:** A. Klinefelter syndrome
**Core Concept:**
Klinefelter syndrome is a genetic disorder that occurs in males, resulting from an extra X chromosome (47, XXY karyotype). This condition affects the development and function of male reproductive and endocrine systems, leading to hypogonadism (reduced or absent testicular function). Hypogonadism and the characteristic XXY karyotype are key features that distinguish Klinefelter syndrome from other conditions with similar presentations.
**Why the Correct Answer is Right:**
Klinefelter syndrome is specifically associated with an extra X chromosome (47, XXY karyotype), which disrupts the normal development of male sex characteristics and testicular function. Hypogonadism is a hallmark feature of this condition due to reduced or absent testicular function, leading to infertility, gynecomastia, and other clinical manifestations.
**Why Each Wrong Option is Incorrect:**
A. Turner syndrome: This is a genetic disorder affecting females (45, X karyotype), resulting in various developmental abnormalities. Hypogonadism is not a primary feature of Turner syndrome, making it an incorrect choice.
B. Congenital adrenal hyperplasia: This is a group of genetic disorders affecting the adrenal glands, leading to impaired cortisol production. Hypogonadism is not a primary feature of congenital adrenal hyperplasia, making it an incorrect choice.
C. Polycystic ovary syndrome (PCOS): PCOS is a hormonal disorder affecting females, characterized by polycystic ovaries and hormonal imbalances. Hypogonadism is not a primary feature of PCOS, making it an incorrect choice.
**Clinical Pearl:**
Understanding the key features of Klinefelter syndrome, such as the XXY karyotype and hypogonadism, is essential for accurate diagnosis and treatment planning. This information is crucial for clinicians managing patients with infertility, gynecomastia, and other signs and symptoms related to reduced testosterone production.